41 patients filled a second prescription for a narcotic within 30 days, a refill rate of 15.4%. Compared to the patients who did not require a refill, these patients were more likely to have been taking narcotics in the pre-operative period(43.3% vs 87.8%, P<0.001). Of the 41 patients who required a narcotic refill, 36 patients were on preoperative narcotics and of the remaining 5 who were not, 3 had a high grade complication and one patient had metastatic disease at the time of surgery. Therefore, of the 267 patients who underwent radical cystectomy, only 1 opioid naive, non-metastatic patient without a high grade complication required an additional prescription for a narcotic within one month of surgery.
INTRODUCTION AND OBJECTIVES: Key opinion leaders have become intimately entwined with the marketing of pharmaceuticals and medical devices. There is currently no consensus on what constitutes a key opinion leader and no quantitative mechanism for identifying them. We explored the utility of a new metric for identifying key opinion leaders and their influence on local prescription patterns.
METHODS: Using abiraterone and enzalutamide as a model, we defined key opinion leaders as those physicians receiving the top payment in a health referral region (HRR). HRRs were delineated according to the Dartmouth Health Atlas. Physicians, including key opinion leaders, were grouped into the HRRs by zip code. Payment data was abstracted from the 2016 Open Payments Database and linked to the Medicare Part D database for prescription count and drug cost.
RESULTS: Across the 306 health referral regions, the median top payment was $188 and $176 for enzalutamide and abiraterone, respectively. The median number of prescriptions was 126 for enzalutamide and 147 for abiraterone. There was a significant correlation between increasing top payment to an individual and increasing total prescriptions in the same region (enzalutamide rho [ 0.69, p < 0.001; abiraterone rho [ 0.65, p < 0.001) CONCLUSIONS: The Open Payments database may be used to establish a quantitative metric for identifying key opinion leaders and early analysis indicates that higher paid individuals motivate more prescriptions from other physicians in their region. In June of 2011, the US Food and Drug Administration (FDA) released a safety announcement stating healthcare professionals should be aware of the increased risk of high-grade prostate cancer after starting 5-alpha reductase inhibitors (5ARI) including finasteride and dutasteride. This was in response to data from the REDUCE and PCPT trials which demonstrated a small increase in the frequency of Gleason score 8-10 tumor biopsies after 5ARI use. We aimed to evaluate the influence of these trials and the FDA safety warning on the 5ARI prescription practices across a large healthcare system. METHODS: The electronic medical records were used to identify new prescriptions for any 5ARI in the 5 years before and after the 2011 FDA safety announcement. We determined rates of prescription to adjust for changing patient volume over time. In a secondary analysis, the prescription rates of 5ARI over time among men diagnosed with BPH or Prostate cancer during this time interval were compared. The prescription rates were also compared based upon prescribing physician specialty. RESULTS: Over the 11 year study period, 16,610 unique patients were initiated on 5ARI therapy. Accounting for changing healthcare volume over time, there was a relative rate reduction of 41% (1.96% v 1.16%, p<0.001) for all new prescriptions of a 5ARi after the 2011 FDA safety warning. In men receiving prescriptions who carried a diagnosis of BPH (n[7714), there was a 49% relative decrease in the prescription rate (33.7% vs 17.3%. (p<0.001) . In patients with prostate cancer who received a 5ARI (n[975), a 15% relative reduction in new prescriptions was seen in the same time period (10.4% v 8.8% p[0.006). Finally, there was no change in prescription patterns within the urology practice in the 5 years before and after the FDA warning, whereas primary care providers showed a 60% relative reduction in prescription rates (p<0.001).
CONCLUSIONS: Within a large healthsystem, the rate of prescriptions for 5 ARIs has decreased after the FDA safety warning in 2011. This decrease was most pronounced among men with a known diagnosis of BPH who may otherwise benefit from 5ARI treatment of urinary symptoms. Further research is warranted to determine whether these findings reflect national trends.
